PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 11, 2022 | Series A | $10.75M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Agilent Technologies | — | Series A |